Delphi-MD, a groundbreaking real-time diagnostics tool developed by QuantalX Neuroscience, utilizes focused transcranial magnetic stimulation (fTMS) to provide rapid and accurate neurological assessments. Recently cleared by the FDA, this innovative technology offers the potential to significantly improve the diagnosis and management of various neurological conditions.
Delphi-MD: A New Era in Neurodiagnostics
Delphi-MD employs a high-resolution magnetic pulse to stimulate targeted brain networks and measure the resulting electrophysiological responses. These responses are then compared to a database of healthy brain patterns, enabling clinicians to identify abnormalities indicative of neurological disorders. This real-time analysis provides objective, quantifiable data that can aid in early detection and treatment planning.
Applications of Delphi Real-Time Diagnostics Tools
The versatility of Delphi-MD allows for its application across a wide spectrum of neurological conditions. It has shown promise in assisting with the diagnosis of:
- Stroke: Identifying individuals at risk for stroke allows for proactive interventions.
- Dementia: Differentiating between various types of dementia, such as Alzheimer’s, Lewy body dementia, and vascular dementia, can guide treatment strategies.
- Parkinson’s Disease: Delphi-MD can detect subtle changes in brain network activity associated with Parkinson’s disease, potentially enabling earlier diagnosis.
- Normal Pressure Hydrocephalus (NPH): Accurate diagnosis of NPH is crucial for determining appropriate treatment, such as ventriculoperitoneal shunt surgery.
- Traumatic Brain Injury: Assessing the extent of brain damage after trauma can inform rehabilitation plans.
- General Brain Health Assessment: Delphi-MD can provide a comprehensive overview of brain function, aiding in the early detection of potential issues.
How Delphi-MD Works: A Seamless Integration
The Delphi-MD system is designed for seamless integration into existing clinical workflows. The process involves:
- Patient Information Input: Entering patient data into the user-friendly interface.
- Brain Network Stimulation: Using a stimulating probe, specific brain network hubs are targeted with high-resolution magnetic pulses.
- Response Recording: A sensor-laden cap records the evoked electrophysiological responses.
- Automated Analysis: The system automatically processes and analyzes the data, generating a comprehensive clinical report within minutes.
Advantages of Delphi Real-Time Diagnostics
Delphi-MD offers several key advantages over traditional neurodiagnostic methods:
- Non-invasive: The procedure is entirely non-invasive, eliminating the need for surgery or injections.
- Real-Time Analysis: Results are available within minutes, facilitating timely diagnosis and treatment decisions.
- Objective and Quantitative: The data provides objective, measurable insights into brain function.
- Point-of-Care Capabilities: Its portability allows for use in various healthcare settings.
- Early Detection: The sensitivity of Delphi-MD enables the early detection of subtle brain abnormalities.
Delphi-MD: Transforming Neurological Care
Delphi-MD has received breakthrough device designation from the FDA and a dedicated CPT reimbursement code, further solidifying its potential to revolutionize neurological care. By providing clinicians with powerful real-time diagnostics tools, Delphi-MD empowers them to make more informed decisions, ultimately leading to improved patient outcomes. This innovative technology promises to transform the landscape of neurology and pave the way for a new era of personalized brain health management.
REFERENCES
- QuantalX Secures FDA Clearance for its breakthrough Delphi stimulator, advancing direct brain health diagnosis at the point of care. News Release. Published November 12, 2024. Accessed January 3, 2024. https://quantalx.com/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct-brain-health-diagnosis-at-the-point-of-care/
- QuantalX Secures Spot in FDA’s Prestigious Total Life Cycle Advisory Program (TAP). News Release. Published April 4, 2024. Accessed January 3, 2024. https://quantalx.com/quantalx-secures-spot-in-fdas-prestigious-total-life-cycle-advisory-program-tap/
- QuantalX Secures Dedicated Reimbursement Code for Delphi-MD Test, Advancing Improved Brain Health. News Release. Published November 2, 2023. Accessed January 3, 2024. https://quantalx.com/quantalx-secures-dedicated-reimbursement-code-for-delphi-md-test-advancing-improved-brain-health/
- Zifman N, Levy-Lamdan O, Hiller T, et al. TMS-evoked potentials unveil occipital network involvement in patients diagnosed with Parkinson’s disease within 5 years of inclusion. NPJ Parkinsons Dis. 2024;10(1):182. Published 2024 Sep 30. doi:10.1038/s41531-024-00793-0
- QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson’s Disease. News Release. Published October 29, 2024. Accessed January 3, 2024. https://quantalx.com/delphi-md-revolutionizes-parkinsons-differential-diagnosis/
